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Analysis of active components in Salvia miltiorrhiza injection 
based on vascular endothelial cell protection
Correlation analysis based on chromatograms and pharma-
cological activities is essential for understanding the effec-
tive components in complex herbal medicines. In this report, 
HPLC and measurement of antioxidant pro per ties were 
used to describe the active ingredients of Salvia miltiorrhiza 
injection (SMI). HPLC results showed that tanshinol, proto-
catechuic aldehyde, rosmarinic acid, salvianolic acid B, pro-
tocatechuic acid and their metabolites in rat serum may con-
tribute to the efficacy of SMI. Assessment of antioxidant 
properties indicated that differences in the composition of 
serum powder of SMI caused differences in vascular endo-
thelial cell protection. When bivariate correlation was car-
ried out it was found that salvianolic acid B, tanshinol and 
protocatechuic aldehyde were active components of SMI be-
cause they were correlated to antioxidant properties.
Keywords: Salvia miltiorrhiza injection, HPLC, antioxidant 
activity, correlation analysis, salvianolic acid
Herbal medicines and their derivatives are widely used as therapeutics in many coun-
tries (1). Radix Salviae miltiorrhizae, called ”Danshen” in China, is one of the most important 
traditional Chinese herbs and is accepted as a health product in western countries owing 
to its remarkable and reliable biological activities, especially in the treatment of cardiovas-
cular disorders (2). Salvia miltiorrhiza products commonly include tablets, pills, and injec-
tions (3). Formulation of Salvia miltiorrhiza dripping pills has been certified by the US FDA 
Phase II clinical trials. Salvia miltiorrhiza injection (SMI) is believed to be another potential 
herbal product and has been the subject of recent studies.
SMI made from the aqueous extract of Radix Salviae miltiorrhizae is widely prescribed 
to patients with coronary disease, unstable angina, brain hemorrhage, cerebral thrombosis 
and cerebrovascular diseases in Chinese clinics (3–5). In addition, it is also applied to treat 
other diseases, such as liver dysfunction, renal deficiency and diabetic vascular complica-
tions (4). Studies of SMI showed that phenolic acids are beneficial compounds, responsible 
for therapeutic efficacy (5–8). Moreover, it is worth noting that phenolic acids of Radix 
Salviae miltiorrhizae such as salvianolic acid A, salvianolic acid B and rosmarinic acid have 
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damage (9, 10). Other studies showed that the water soluble extract of Radix Salviae miltior-
rhizae exhibited high reactive oxygen species scavenging activity (11, 12). Many methods 
have been developed for chemical and pharmacological investigations of SMI, including 
chemical analysis with HPLC-UV, HPLC-MS, UPLC-MS, HPLC-CL and in vivo / in vitro 
pharmacological studies (13–18). However, there are few reports on ingredient analysis of 
SMI correlated to its biological activity. 
Though we have already reported a simultaneous detection of seven phenolic acids in 
SMI (13), investigations in which phenolic acids have higher correlation to cardiovascular 
protection are more meaningful but have not been published yet. Therefore, in this paper, 
we present a study correlating phenolic acids in serum powder of SMI to its vascular en-
dothelial cell protection by the use of bivariate correlation analysis (e.g., ref. 19).
EXPERIMENTAL
Chemicals
Standards including tanshinol (99.8 %), protocatechuic aldehyde (99.8 %), protocate-
chuic acid (99.8 %), rosmarinic acid (99.8 %) and salvianolic acid B (99.5 %) were purchased 
from the National Institute for the Control of Pharmaceutical and Biological Products 
(China). Salvianolic acid A was isolated from the aqueous extract of Radix Salviae miltior-
rhizae and was identified on the basis of mass spectrum data; its purity was over 97 % (by 
HPLC analysis). SMI was kindly supplied by Qinchunbao Pharmaceutical Co., Ltd. (Chi-
na). Methanol, acetonitrile and formic acid (Merck, Germany) were of HPLC grade. Cho-
lestan-3b,5a,6b-triol (triol), superoxide dismutase (SOD) kits and 1,1-diphenyl-2-picrylhy-
drazyl (DPPH) were purchased from Sangon Biotech Co., Ltd. (China). Materials used for 
cell experiments including human umbilical vein endothelial cells (HUVECs), Dulbecco’s 
modified Eagle’s medium (DMEM), fetal calf serum (FCS), recombinant human basic fibro-
blast growth factor (bFGF), bovine serum albumin (BSA) and 4’,6-diamidino-2-phenylin-
dole (DAPI) were also purchased from Sangon Biotech Co., Ltd. Deionized water used 
throughout the experiments was produced using a Mill-Q water purification system (Mil-
lipore, USA).
Animals and blood samples
Female Sprague Dawley rats (clean grade), weighting 220–250 g, were obtained from 
the Zhejiang Academy of Medical Sciences (Hangzhou, China). The studies were approved 
by the Animal Ethics Committee of Zhejiang Chinese Medical University (Hangzhou, 
China). Rats were fasted overnight, with free access to water, before the experiment. They 
were then randomly assigned into six groups (groups 1–6, n = 6 each). Groups 1–6 were 
given SMI, 630 mg kg–1 by intravenous injection.
Blood samples (0.2 mL) were collected from the ophthalmic venous plexus in heparin-
ized polythene tubes just before drug injection and 5 (group 1), 10 (group 2), 15 (group 3), 
20 (group 4), 25 (group 5) and 30 (group 6) min after injection. Serum was separated quick-
ly using centrifugation at 1600×g for 10 min. One mL acetone was added to serum and 
centrifuged at 3000×g for 10 min to remove proteins. The supernatant was concentrated to 
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the serum powder of SMI with a vaccum concentrator (Savant SPD121P, Savant SpeedVac 
Concentrator, Thermo Scientific, USA) set at 4 °C. Finally the serum powder of SMI was 
stored at –80 °C until analysis. Serum powder of SMI was dissolved in methanol and the 
solution was injected into HPLC system to analysis. Serum powder of SMI when dissolved 
in deionized water was used for the cells.
Cells
HUVECs were seeded at 5 × 104 cm–2 and cultured in DMEM supplemented with 100 
units mL–1 penicillin, 100 µg mL–1 streptomycin, 20 % (V/V) FCS and 10 ng mL–1 bFGF for 
24 hours. The medium was changed to DMEM supplemented with 0.1 % BSA, 10 ng mL–1 
bFGF and various concentrations of cholestan-3b,5a,6b-triol. The number of cells in the 
confluent culture did not change significantly in the serum-free medium over the subse-
quent 48 hours unless triol was added. Cells between passages 2 to 7 were used for ex-
periments.
HUVECs were stained with 500 ng mL–1 of DAPI for 10 min at room temperature. The 
number of apoptotic cells (approximately 1000–2000 cells per well) was counted for nine 
high power fields under a fluorescent microscope. Apoptotic cells were defined as cells 
with fragmented and/or more apoptotic bodies and their percentage was calculated.
HPLC
The HPLC equipment used was an Agilent 1100 series system (Agilent Technologies, 
USA) consisting of a binary pump, online vacuum degasser, autosampler, thermostated 
column compartment and multiple wavelength detection. A Tigerkin C18 column (200×4.6 
mm i.d., 5.0 µm) from Dalian Sipore Co. (China) was used for all chromatographic separa-
tions. The HPLC analytical conditions, which we developed before, were used in the assay. 
Linear gradient elution of eluents A [0.5 % (V/V) aqueous formic acid] and B [0.5 % (V/V) 
formic acid in acetonitrile] was used to run the separation. The first linear gradient was 
5–20 % eluent B in the range of 0–10 min, the second was 20–25 % eluent B in the range of 
10–17 min, and the last one was 25–55 % eluent B in the range of 17–35 min. The system 
was restored to initial conditions after 5 min. The solvent flow rate was 1.0 mL min–1, injec-
tion volume was 20 µL, and column temperature was maintained at 30 °C. Chromato-
grams were recorded at 280 nm in the range of 0–13 min, 326 nm in the range of 13–23.5 
min, and at 286 nm in the range of 23.5–35 min. Chemstation software (Agilent Technol-
ogy) was used for peak detection and peak area calculation.
Free radical scavenging activity and antioxidant activity of serum powder of SMI
Free radical scavenging activity was determined as described by Blois (20). Briefly, 
acetate buffer (100 mmol L–1, pH 5.5), ethanol (100 %) and freshly prepared 500 nmol L–1 
DPPH solution in ethanol were mixed in a volume ratio 1:1:0.5. After the test compound 
was added, the mixture was incubated at 25 °C for 90 min. The change in absorption at 517 
nm was then determined with a spectrophotometer (TU-1901 double-beam UV-Vis spec-
trophotometer, China).
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Antioxidant properties were evaluated by measuring SOD activity. The experiment 
was performed using the SOD kit according to the manufacturer’s instructions.
Drug preparation
SMI was prepared by the Qinchunbao Pharmaceutical Co., Ltd (China). It was made 
from the extract of Radix Salviae miltiorrhizae and prepared according to the standard injec-
tion production process. It was stored at 4 °C. SMI was diluted with a 50 % glucose injection 
in a volume ratio 1:5; the dilution should be freshly prepared prior to injecting it to the rats.
Statistical analysis
The data of free radical scavenging activity and antioxidant properties were present-
ed as mean ± standard error of the mean (SEM). Bivariate correlation was tested using the 
SPSS Version 17.0 software package (SPSS, USA) to analyze the correlation between the 
peak areas and antioxidant properties. Pearson correlation coefficients were obtained by 
bivariate correlation.
RESULTS AND DISCUSSION
HPLC chromatograms of SMI serum powder 
Six groups of SMI serum powder were analyzed by HPLC. Tanshinol, protocatechuic 
aldehyde, rosmarinic acid, salvianolic acid B, protocatechuic acid and some metabolites 
were found in the serum powder of SMI (Fig. 1). As shown in Fig. 1 the retention time of peak 
4a was close to the retention time of rosmarinic acid; however, this peak did not appear in 
the chromatogram of SMI. Thus it may be the metabolite of rosmarinic acid. Similar cases 
were peak 5a (the metabolite of salvianolic acid B) and peak 6a (the metabolite of salvianolic 
acid A). These metabolites and protocatechuic acid were found only in the serum powder of 
SMI. In addition, tanshinol, protocatechuic aldehyde, rosmarinic acid and salvianolic acid B 
which existed in SMI were also found in the serum powder of SMI (Table I). The ingredients 
that exist in the serum may be the active components. Therefore, tanshinol, protocatechuic 
aldehyde, rosmarinic acid, salvianolic acid B, protocatechuic acid and the metabolites may 
contribute to the efficacy of SMI.
Serum powder of SMI inhibits endothelial cell apoptosis
Serum powder of SMI prevented the triol-induced apoptosis of human umbilical vein 
endothelial cells in vitro (Fig. 2). In the assay, 5 µg mL–1 of triol induced apoptosis in HU-
VECs in a time-dependent manner in vitro. Triol induced significant apoptosis in HUVECs 
as early as 24 h from the start of incubation, and the number of apoptotic cells increased 
up to 48 h. When 100 µg mL–1 of SMI serum powder was added into the HUVECs with 5 
µg mL–1 of triol, the number of apoptotic cells decreased significantly (inhibition 47.6 %, 
p < 0.05) vs. reference drug probucol (inhibition 72.1 %, p < 0.01), in contrast to the blank 
control. In short, serum powder of SMI could inhibit the triol-induced apoptosis of 
 HUVECs and protect normal HUVECs in vitro.
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Fig. 1. HPLC chromatograms of: a) serum powder of SMI, b) blank control, c) standard, d) six groups 
of SMI serum powder (D-1 to D-6) and e) SMI. Components: 1 – tanshinol, 2 – protocatechuic acid, 3 – 
protocatechuic aldehyde, 4 – rosmarinic acid, 5 – salvianolic acid B, 6 – salvianolic acid A, 4a – metabo-
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Table I. Components in SMI and SMI serum powder
Component Content in SMI (mol L–1)a Content in serum powder of SMI (mol L–1)a
Tanshinol 2.34 ± 0.04 (9.10 ± 1.74) × 10–2
Protocatechuic aldehyde 1.96 ± 0.02 (1.70 ± 0.05) × 10–2
Salvianolic acid B 0.42 ± 0.01 (1.56 ± 0.04) × 10–2 
a Mean ± SD (n = 6).
Table II. Radical scavenging activity and SOD activity of SMI serum powder in HUVECs induced by triolb 
for 48 h by DPPH assay 
Group IC50 (µg mL–1) SOD (U mL–1)
1 57.6 ± 2.4c 0.53 ± 0.05
2 52.4 ± 1.9c 0.58 ± 0.05c
3 49.3 ± 1.7c 0.63 ± 0.03c
4 54.7 ± 2.2c 0.54 ± 0.02
5 56.9 ± 2.2c 0.51 ± 0.05
6 58.3 ± 2.9c 0.46 ± 0.04
Negative control (triol) 174.1 ± 6.5 0.21 ± 0.04 
Positive control (probucol) 35.6 ± 1.3c 0.79 ± 0.03c
Values were mean ± SEM (n = 6).
a Concentration of SMI: 100 µg mL–1.
b Concentration of triol: 5 µg mL–1.
c p < 0.05 compared with triol
Six groups of serum powder of SMI and probucol were added into the triol-induced 
apoptotic HUVECs. Apoptosis of endothelial cells was inhibited significantly (p < 0.05) in 
groups of SMI serum powder (Fig. 3). 
Free radical scavenging activity and antioxidant activity of SMI serum powder 
Serum powder of SMI exhibited free radical scavenging activity in the 1,1-diphenyl-2- 
-picrylhydrazyl (DPPH) assay. The results are listed in Table II. As shown in Table II, all 
groups of SMI serum powder showed good radical scavenging activity, with the IC50 val-
ues from 49.3 ± 1.7 to 58.3 ± 2.9 µg mL–1 in contrast to triol (174.1 ± 6.5 µg mL–1). Groups 3 
and 2 were the best. The radical scavenging activity of serum powder of SMI was 1.5 times 
lower than that of the reference drug probucol (35.6 ± 1.3 µg mL–1).
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Fig. 2. The time course for HUVECs cultured in SMI serum powder (X-type), SMI serum powder with 
5 µg mL-1 of triol (closed triangle), blank control (open square) or 5 µg mL-1 of triol (closed square) for 
48 h. Each point represents the mean ± SEM (n = 6).
Fig. 3. The effect of SMI serum powder on the triol-induced apoptosis of HUVECs. a – triol, b – group 
D-1 (5 min), c – group D-2 (10 min), d – group D-3 (15 min), e – group D-4 (20 min), f – group D-5 
(25 min), g – group D-6 (30 min), h – probucol. Each point represents the mean ± SE (n = 6). Signifi-
cantly different from triol: * p < 0.05, ** p < 0.01.
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The activity of superoxide dismutase was used as an index of oxidative damage in the 
assay. All groups of serum powder of SMI increased the low activity of SOD caused by 
triol (SOD value of 0.21 ± 0.04 U mL–1). As shown in Table II, group 3 was better (0.63 ± 0.03 
U mL–1) than the other groups.
Correlation analysis based on the chromatograms and antioxidant properties of SMI 
serum powder 
According to the results shown in Table III, the area of four peaks in HPLC chromato-
grams showed higher correlation to radical scavenging activity than the others, with the 
absolute correlation coefficient value higher than 0.7. These four compounds were salviano-
lic acid B, tanshinol, protocatechuic aldehyde and rosmarinic acid. Among them, salvianolic 
acid B reached the significance level with p < 0.01 and tanshinol and protocatechuic aldehyde 
with p < 0.05. Since correlation between IC50 and peak area appeared in protocatechuic acid 
and rosmarinic acid metabolite, we suggest that the two components had no free radical 
scavenging activity. Neither did metabolites of salvianolic acid B and A, due to their low R. 
Peak areas of salvianolic acid B, tanshinol, protocatechuic aldehyde and rosmarinic acid 
showed higher correlation to SOD activity than the other components (Pearson correlation 
coefficient R > 0.6). Among them, salvianolic acid B, tanshinol and protocatechuic aldehyde 
reached the significance level with p < 0.05. Our findings suggest that protocatechuic acid 
and the rosmarinic acid metabolite had almost no antioxidant activity. Furthermore, low R 
between peak area and SOD activity suggested that metabolites of salvianolic acid B and A 
were unrelated to antioxidant activity.
This method enables rapid identification of active components in herbal medicine and 
provides a meaningful tool for their quality control.
Table III. Pearson correlation coefficient between peak area and antioxidant property of ingredients in SMI 
serum powder
Compound Retention time (min)
Peak area vs. 
IC50
Peak areas vs. 
SOD 
Tanshinol 7.899 –0.880a 0.861a
Protocatechuic acid 9.691 0.398 –0.440
Protocatechuic aldehyde 10.901 –0.722a 0.807a
Metabolite of rosmarinic acid 21.901 0.005 –0.139
Rosmarinic acid 22.530 –0.773 0.654
Metabolite of salvianolic acid B 23.388 –0.227 0.129
Salvianolic acid B 24.349 –0.954b 0.911a
Metabolite of salvianolic acid A 27.523 –0.449 0.279
a Significance level of correlation (p < 0.05).
b Significance level of correlation (p < 0.01).
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Based on these results, it was concluded that salvianolic acid B, tanshinol and protocat-
echuic aldehyde correlated well with the antioxidant properties of serum powder of SMI. 
They contributed to the protection of vascular endothelial cells by inhibiting the triol-in-
duced apoptosis of HUVECs and protecting normal HUVECs in vitro. They were shown for 
the first time to be antioxidants by correlation analysis. Salvianolic acid B was demonstrated 
to be the most potential antioxidant of all the SMI ingredients, since it was closely related to 
the free radical scavenging activity and SOD activity with the Pearson correlation coefficient 
higher than 0.9. In future experiments, we will identify the metabolites of SMI and a sys-
tematic study of pharmacokinetics of SMI will be carried out.
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